Centro de Investigación Cooperativa en Biomateriales-ko ikertzaileekin lankidetzan egindako argitalpenak (3)

2023

  1. Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model (Frontiers in Pharmacology, (2023), 14, (1021535), 10.3389/fphar.2023.1021535)

    Frontiers in Pharmacology

  2. Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

    Frontiers in Pharmacology, Vol. 14

2020

  1. Probiotic Bifidobacterium breve prevents DOCA-salt hypertension

    FASEB Journal, Vol. 34, Núm. 10, pp. 13626-13640